For Research Purposes Only • Not For Human Consumption
Fat Loss / Metabolic
Tirzepatide 30mg
Dual GLP-1 / GIP agonist — metabolic and weight regulation.
$22010 LEFT
Tirzepatide is a dual agonist of the GLP-1 and GIP receptors. It improves glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying and produces marked appetite suppression in research subjects.
Benefits
- Significant fat-mass reduction
- Improved HbA1c and fasting glucose
- Reduced cravings and caloric intake
- Favorable lipid panel shifts
Considerations
- Nausea, reflux, constipation, diarrhea (dose-dependent)
- Possible gallbladder issues with rapid loss
- Risk of muscle loss without adequate protein/training
- Injection-site reactions
Protocol
Subcutaneous, once weekly. Start low and increase every 4 weeks as tolerated. Typical cycle 12–20 weeks.
Dosage
Titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly. Most users plateau between 5–10 mg.
Reconstitution
10 mg vial + 2 mL BAC water = 5 mg/mL (0.1 mL = 2.5 mg). 30 mg vial + 3 mL BAC water = 10 mg/mL.
Always use bacteriostatic water (BAC), sterile technique and store reconstituted vials refrigerated unless otherwise noted.
Research Use Only. All information shown is summarized from publicly available research literature for educational reference only. These compounds are not approved for human consumption and nothing here is medical advice.
